POPULARITY
7 episodes with spinal cord stimulation
2 episodes with spinal cord stimulation
2 episodes with spinal cord stimulation
2 episodes with spinal cord stimulation
4 episodes with spinal cord stimulation
2 episodes with spinal cord stimulation
2 episodes with spinal cord stimulation
2 episodes with spinal cord stimulation
2 episodes with spinal cord stimulation
We have a great show for you this week which will provide all of the answers you have come to expect from The Word on Medicine. This Saturday, our program is on Chronic Back Pain and Spinal Cord Stimulation: medical experts and a patient discuss the challenges of chronic pain, primarily back and leg pain. They discuss the various treatment options, with a focus on spinal cord stimulation. Please join Drs. Peter Pahapill, Sarah Endrizzi and their patient for this important show!
Dr. Anna Latorre is interviewed by Dr. Sara Schaefer about her study exploring the role of transcutaneous spinal cord simulation for suppression of postural tremor in essential tremor, including the potential pathophysiological mechanisms and implications for therapeutic use. Journal CME is available until October 21, 2025 Read the article.
Check the end of any recent study, and there will be a list of study funders and disclosures about competing interests. It's important to know about potential biases in research, but this kind of transparency was not always the norm. Understanding bias in research and helping policymakers use the most reliable evidence to guide their decisions is a science in itself. Lisa Bero, a professor at the University of Colorado Anschutz Medical Campus, has been at the forefront of understanding how corporate funding biases research and how to assess what scientific evidence is reliable. She talks to host Monya Baker about her investigations into the tobacco and pharmaceutical industries, techniques industries use to shape evidence to favor their products, and the importance of independent research to inform policy. Resources: Read The Cigarette Papers to learn more about Lisa Bero and others' investigations of the tobacco industry. See this analysis of industry documents about insider knowledge of health effects of PFAS and related chemicals. Visit the Cochrane Library to find more systematic reviews of clinical research. Learn more about Adrian Traeger's investigation of spinal cord stimulation research by reading Corporate Influences on Science and Health—the Case of Spinal Cord Stimulation. Read Lisa Bero's summary of how industry forces suppress unfavorable research. Lisa Bero and others are developing a tool to screen for signs of fraud in clinical research. Learn more about it in The Conversation.
A lot has happened in the last two weeks! Make sure you check out the last episode featuring Dr. Brian Parnes, and then get ready to learn more about Spinal Cord Stimulators (SCS) and Sacral Nerve Stimulation (SNS). Robby just had his trial implant for a SNS device, and he is happy to share to how well it's working for him. In fact, the day this episode drops he is actually going back into surgery to get his device permanently implanted! Follow the show on Instagram @thepainfultruthpodcast, as well as Robby @robert1950studios and Sammi @thesam.a.lamCheck out their TikTok @1950StudiosYou can find Limitless Broadcasting on Instagram @limitlessbroadcasting.Rant Radio is LIVE! Call 844-857-7268 and leave your rant today. Check out LimitlessBroadcastingNetwork.com for all of our podcasts, subscriptions, and to pick up some awesome merch!
In this episode of RAPM Focus, Editor-in-Chief Brian Sites, MD, is delighted to be joined by Ryan D'Souza, MD, and Nasir Hussain, MD, following the February 2024 publication of their review, “Methodological and Statistical Characteristics of Meta-Analyses on Spinal Cord Stimulation for Chronic Pain: A Systematic Review.” Both of these anesthesiologists are prolific in their research and contributions to the regional anesthesia and pain medicine community. Best practice advisories and policies tend to stem from the results of systematic reviews and metanalysis, thus the stakes are very high for a journal to ensure that the results are meaningful and valid. The mathematical principles and assumptions of systematic reviews and meta-analyses are quite complex, which often exceeds the capacity of many journals to truly adjudicate. To further complicate matters, there are emerging techniques that include network meta-analyses that take even more expertise to review. Therefore, better understanding content areas where there are strengths and weaknesses around systematic reviews is critical to best informing clinical practice. Dr. D'Souza is a pain medicine physician and anesthesiologist at the Mayo Clinic. He is an associate professor, director of neuromodulation, and director of the in-patient pain service. He is an associate editor and social media editor for RAPM. Dr. Hussain is a pain medicine physician and anesthesiologist at the Ohio State University Wexner Medical Center. He is an assistant professor, associate program director for anesthesiology residency, and assistant program director of the chronic pain fellowship. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on X @RAPMOnline, Facebook @Regional Anesthesia & Pain Medicine, and Instagram @RAPM_Online.
Dr. Robert Baranello discusses the growing field of neurmodulation. In part 1, he covers some of the indications for Spinal Cord Stimulation, Peripheral Nerve Stimulation, Ganglion Root Stimulation, and more. Dr. Baranello practices Interventional Pain Management at the Durham office of EmergeOrtho. For more information, check out Https://www.robertbaranellomd.wordpress.com/ https://www.instagram.com/baranello_paindoc/ Register for our next conference at PAOS.org! Join us in Nashville in September - spaces are filling quickly!
What is Spinal Cord Stimulation and how does it work? What are the risks and how are those risks mitigated by medical professionals? Dr. Deer is at the forefront of spinal cord stimulation research and in this episode he discusses the various aspects of Spinal Cord Stimulators that patients and doctors need to be aware of. Dr. Deer may be reached through https://centerforpainrelief.com/doctor-timothy-deer/ Dr. Deer founded the Spine and Nerve Centers of the Virginias in 1994. The Center has grown to offer treatment to not only West Virginians and Virginians, but also to many patients from throughout the United States, and those who travel Internationally for ground breaking interventional treatments often pioneered with the help of the team at our facilities. Dr. Deer has led a revolution in interventional spine and nerve care by teaching thousands of physicians an algorithmic approach to care including methods that are less invasive at a lower risk for complications. Dr. Deer completed his Medical Degree at West Virginia University at the top of his class, and then went on to complete his advanced training at the University of Virginia. He currently holds the position of as a Clinical Professor of Anesthesiology at WVU and is active in teaching medical students, and hosts many residents and fellows for advanced training from both the United States and many countries. In addition to those positions, Dr. Deer is on the Board of Directors for the North American Neuromodulation Society. He is also on the editorial committee for the journals Neuromodulation, Pain Medicine, and Pain Physician.
Broadcast from KSQD, Santa Cruz on 6-20-2024 Health tip: Dr. Dawn advises you to shop around for medications, especially cheap generics, as pharmacies may claim unavailability due to corporate contracts and profit margins. Healthcare industry consolidation: Discussion of how large venture capital firms are acquiring healthcare businesses, leading to potential price increases and reduced competition. Parkinson's disease and GLP-1 drugs: A study showing potential benefits of GLP-1 receptor agonists like Ozempic in early Parkinson's disease. Bird flu update: Current status of bird flu spread in the US, transmission risks, and safety precautions. Spinal cord stimulation: New non-invasive technique showing promise for improving function in people with long-term spinal cord injuries. Peanut allergies: Recent research reversing previous recommendations, suggesting early exposure to peanuts may reduce allergy risk. Longevity study: Analysis of blood biomarkers in centenarians, highlighting factors like uric acid levels and blood sugar. Cholesterol-eating gut bacteria: Research on bacteria that break down cholesterol in the gut, potentially lowering heart disease risk. Alcohol and air travel: Study showing combined effects of alcohol consumption and low air pressure on cardiovascular health during flights. Energy requirements of pregnancy: Surprising findings on the high caloric needs during pregnancy, mostly for the mother's body rather than the fetus. HPV vaccine success: Significant reduction in cervical cancer rates due to the vaccine, with a call for increased vaccination rates, especially among boys, to prevent head and neck cancer.
This episode is sponsored by Medtronic.Painful diabetic peripheral neuropathy (DPN) can significantly impact a person with diabetes and their quality of life. Nalani Hunsaker PA-C, MCMSc, BC-ADM, a paid consultant for Medtronic, joins The Huddle to talk about Medtronic's spinal cord stimulation therapy option, how the procedure works, and its success in relieving pain from DPN. Please reach out to http://www.medtronic.com/dpnconnect to connect with a Medtronic representative today. If you would like to share more information with your patients check out http://www.medtronic.com/dpnpain References:1. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: A multicentre randomized clinical trial. Pain. 2014;155(11):2426–2431. doi:10.1016/j.pain.2014.08.031 2. Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: A prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016–3024. doi:10.2337/dc14-0684 3. Medtronic Pain Therapy Clinical Summary M221494A016 Rev B. United States; 2022. 4. van Beek M, Geurts JW, Slangen R, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: Five-year follow-up of a prospective two-center clinical trial. Diabetes Care. 2018;41(1):32–38. doi:10.2337/dc17-0983 5. Zuidema X et al. Long-term Evaluation of Spinal Cord Stimulation in Patients With Painful Diabetic Polyneuropathy: An Eight-to-Ten-Year Prospective Cohort Study. Neuromodulation. 2022 Dec 30:S1094-7159(22)01403-9. 6. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. 2019;380(20):1895-19057. Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine (Phila Pa 1976). 2015 1;40(9):E531-7.8. Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8 https://creativecommons.org/licenses/by/4.0/.9. Temel Y, Ackermans L, Celik H, et al. Management of hardware infections following deep brain stimulation. Acta Neurochir (Wien). April 2004;146(4):355-361.10. Pepper J. Zrinzo L, Mirza B, Foltynie T, Limousin P, Hariz M. The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure. Stereotact Funct Neurosurg. 2013;91(1):56-65.11. Tolleson C, Stroh J, Ehrenfeld J, Neimat J, Konrad P, Phibbs F. The factors involved in deep brain stimulation infection: a large case series. Stereotact Funct Neurosurg. 2014;92(4): 227-233.12. Thrane JF, Sunde NA, Bergholt B, Rosendal F. Increasing infection rate in multiple implanted pulse generator changes in movement disorder patients treated with deep brain stimulation. Stereotact Funct Neurosurg. 2014;92(6):360-364.13. Deer TR, Provenzano DA, Hanes M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management [published correction appears in Neuromodulation. July 2017;20(5):516]. Neuromodulation. January 2017;20(1):31-50.14. Mekhail NA, Mathews M, Nageeb F, Guirguis M, Mekhail MN, Cheng J. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. Pain Pract. March-April 2011;11(2):148-153.15. Falowski SM, Provenzano DA, XIa Y, Doth AH. Spinal Cord Stimulation Infection Rate and Risk Factors: Results From a United States Payer Database. Neuromodulation. February 2019;22(2):179-189.16. Clifton M, Quirouet A, Pizarro-Berdichevsky J, et al. Infection rate after sacral neuromodulation surgery: a review of 1033 InterStim procedures. J Urol. April 2016;195(4S):851.17. Bjerknes S, Skogseid IM, Sæhle T, Dietrichs E, Toft M. Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period. PLoS One. August 14, 2014;9(8):e105288.18. Piacentino M, Pilleri M, Luigi Bartolomei L. Hardware-related infections after deep brain stimulation surgery: review of incidence, severity and management in 212 single-center procedures in the first year after implantation. Acta Neurochir (Wien). December 2011; 153(12):2337-2341.19. Hamani C, Lozano AM. Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg. 2006;84(5-6):248-251.20. Hayek SM, Veizi E, Hanes M. Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience From an Academic Center Database. Neuromodulation. October 2015;18(7):603-608. 21. Bendel MA, O'Brien T, Hoelzer BC, et al. Spinal Cord Stimulator Related Infections: Findings From a Multicenter Retrospective Analysis of 2737 Implants. Neuromodulation. August 2017;20(6):553-557. 22. Wexner SD, Hull T, Edden Y, et al. Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence. J Gastrointest Surg. July 2010;14(7):1081-1089.15 23. Chen T, Mirzadeh Z, Lambert M, et al. Cost of Deep Brain Stimulation Infection Resulting in Explantation. Stereotact Funct Neurosurg. 2017;95(2):117-124.24. Provenzano DA, Falowski SM, Xia Y, Doth AH. Spinal Cord Stimulation Infection Rate and Incremental Annual Expenditures: Results From a United States Payer Database. Neuromodulation. April 2019;22(3):302-310.25. Medtronic data on file: Economic Impact of Infection Related to Neuro-Stimulator Implant. Study report prepared for Medtronic prepared by Optum, 2018/01/03.26. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-2735. 27. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. May 16, 2019;380(20):1895-190528. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-273529. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. April 2021. doi:10.1001/jamaneurol.2021.0538 Spinal Cord Stimulation Brief Summary INDICATIONS Spinal cord stimulation (SCS) is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain. CONTRAINDICATIONS Diathermy - Energy from diathermy can be transferred through the implanted system and cause tissue damage resulting in severe injury or death. WARNINGS Sources of electromagnetic interference (e.g., defibrillation, electrocautery, MRI, RF ablation, and therapeutic ultrasound) can interact with the system, resulting in unexpected changes in stimulation, serious patient injury or death. An implanted cardiac device (e.g., pacemaker, defibrillator) may damage a neurostimulator, and electrical pulses from the neurostimulator may cause inappropriate response of the cardiac device. Patients with diabetes may have more frequent and severe complications with surgery. A preoperative assessment is advised for some patients with diabetes to confirm they are appropriate candidates for surgery. PRECAUTIONS Safety and effectiveness has not been established for pediatric use, pregnancy, unborn fetus, or delivery. Avoid activities that put stress on the implanted neurostimulation system components. Recharging a rechargeable neurostimulator may result in skin irritation or redness near the implant site. ADVERSE EVENTS May include: undesirable change in stimulation (uncomfortable, jolting or shocking); hematoma, epidural hemorrhage, paralysis, seroma, infection, erosion, device malfunction or migration, pain at implant site, loss of pain relief, and other surgical risks. Adverse events may result in fluctuations in blood glucose in patients with diabetes. Refer to www. medtronic.com for product manuals for complete indications, contraindications, warnings, precautions and potential adverse events. Rx only. Rev 0422 TYRX™ Neuro Absorbable Antibacterial Envelope Brief Statement The TYRX™ Neuro Absorbable Antibacterial Envelope is intended to hold a vagus nerve stimulator, a spinal cord neuromodulator, a deep brain stimulator or a sacral nerve stimulator securely in order to create a stable environment when implanted in the body. The Neuro Antibacterial Envelope contains the antimicrobial agents Minocycline and Rifampin which, have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of a pulse generator. The Neuro Antibacterial Envelope is NOT indicated for use in patients who have an allergy or history of allergies to tetracyclines, Rifampin, or absorbable sutures. The Neuro Antibacterial Envelope is also NOT indicated for use in patients with contaminated or infected wounds, or Systemic Lupus Erythematosus (SLE). This device is intended to be used in conjunction with vagus nerve stimulators or deep brain stimulators implanted in the infraclavicular fossa, or in conjunction with spinal cord neuromodulators or sacral nerve stimulators implanted laterally to the body midline and slightly superior to the gluteal region. The use of this product in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be considered carefully, because Minocycline and Rifampin can cause additional stress on the hepatic and renal systems. Patients who receive the Neuro Antibacterial Envelope and who are also taking methoxyflurane should be monitored carefully for signs of renal toxicity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
In today's episode, we're joined by Carles Garcia-Vitoria, a seasoned pain physician with a unique approach to his work. With extensive experience in regional anesthesia and pain management, Carles shares insights gained from his years of practical experience as he pursues his PhD in Spain. Top 3 Takeaways: "We believe we have the opportunity to target the site of action more effectively. That's why we've founded Spinally, the startup we're currently leading. Our goal is to pioneer intrathecal spinal cord stimulation." "The Dura Mater is highly elastic, closing approximately 80-90% within the first 30 seconds after trauma. Additionally, with improved intrathecal access and emission capabilities, we can utilize thinner implants—reducing implant thickness from 1.3 to 0.5 millimeters. This minimizes trauma to the meningeal sac even further." "We can leverage new fabrication capabilities to minimize implants and achieve highly effective pain relief. Our models, along with others, indicate that we can stimulate deeper layers of the spinal cord with intrathecal electrode positioning, enhancing our ability to listen to deeper neuronal tracts. This advancement is poised to make significant waves in the pain management field within a year." 0:45 Can you introduce yourself better than I just did? 1:15 What advantages of neurotechnology do you see in the pain market? 3:15 What does the pain treatment process using neuromodulation look like? 6:45 How is closed loop stimulation changing your work? 8:30 You're involved in a startup to better listen to the spinal cord, can you talk about that? 11:30 Why hasn't this been done before? 14:00 Where in the startup process are you? 15:30 Where are you getting the leads from? 16:30 You guys are raising money, can you talk about that? 18:30 Crowdfunding for medical devices is new, have you seen these before? 21:00 Is there anything that we didn't cover that you wanted to mention?
What is spinal cord stimulation? This week, Schuyler Rogg, M.D., M.B.A., who specializes in pain medicine and sees patients as part of the Spine & Pain Program at MyMichigan Health, joins us to talk about spinal cord stimulation.
Visit nascentmc.com/podcast for full show notes [free course] ChatGPT4 in medical writing and editing at learnAMAstyle.com Nascentmc.com for medical writing assistance for your CME or Medical Communications company. Eplontersen for ATTR-CM Eplontersen received FDA Fast Track designation for treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults, aiming to inhibit TTR protein production. Nivolumab for NSCLC The FDA accepted supplemental applications for nivolumab in resectable stage 2A to 3B non-small cell lung cancer (NSCLC) based on the CheckMate-77T trial showing improved survival rates. RSV Vaccine for Adults Aged 50 to 59 The FDA prioritizes review of GSK's Arexvy vaccine for RSV in adults aged 50-59 at risk of complications, expanding from its existing approval for those 60 and older. Spinal Cord Stimulation System The FDA approved Boston Scientific's WaveWriter Spinal Cord Stimulation Systems for chronic low back and leg pain treatment in non-surgery patients, based on the SOLIS trial results. OK-101 for Neuropathic Corneal Pain The FDA approved an IND application for OK-101, a first for treating neuropathic corneal pain (NCP), an Orphan disease, developed by OKYO Pharma Limited. Viz ICH Plus for Brain Bleed The FDA cleared Viz ICH Plus, an AI algorithm by Viz.ai for automating the identification and quantification of brain bleeds and structures in NCCT images. Vepdegestrant for MBC Vepdegestrant received FDA Fast Track designation for treating ER-positive/HER2-negative advanced or metastatic breast cancer in patients previously treated with endocrine therapy. VerTouch Spinal Puncture Device The FDA cleared VerTouch, a handheld imaging tool by IntuiTap Medical, designed to improve the accuracy of spinal punctures by providing a 2D image of lumbar spinal anatomy.
STROKE VICTIMS WHO LOST THE USE OF AN ARM HAVE REGAINED MOBILITY, FOLLOWING A REVOLUTIONARY SPINAL CORD STIMULATION TREATMENT. WE SPEAK WITH DR. MARCO CAPOGROSSO, ASSISTANT PROFESSOR AND DIRECTOR OF THE SPINAL CORD STIMULATION LABORATORY AT THE UNIVERSITY OF PITTSBURGH.
On this episode of the Pain Matters Podcast, we turn our attention to a Viewpoint article published in JAMA on December 18, 2023 entitled “Corporate Influences on Science and Health—the Case of Spinal Cord Stimulation”. Written by the same lead author of the widely criticized Cochrane Review of Spinal Cord Stimulation (SCS) for Low Back Pain, this recent article blames all physicians who defend SCS for having corporate interests and suggests that no research in any specialty should be influenced by industry.Hosts Shravani Durbhakula, MD, MPH, MBA, and Mustafa Broachwala, DO, sit down with Nathaniel M. Schuster, MD, from UC San Diego Health. All are authors to responses in Pain Medicine to the Cochrane Review by Traeger et al. –see Pain Matters Episode 21 and articles PMID: 37067491 & PMID: 37195450 by Durbhakula et al. This episode responds to the questionable allegations made by Traeger et al., questioning the integrity of all SCS research and the pain physicians who utilize SCS for patients. We do a fact-check on the JAMA article and take a deep dive into understanding the true nature of corporate influences on SCS.In this episode, you'll gain insights into:Critiquing Corporate Influence: Dr. Schuster and our hosts examine corporate influence in pain medicine research, particularly in the context of SCS treatments for low back pain.False Dichotomies in SCS Research: The false dichotomy that physician-scientists who may engage with industry at any level cannot be industry-independent when speaking on the subject of SCS.Physician Scientist Integrity: False accusations, including that ALL physicians who responded to the Cochrane Review by Traeger et al,. were influenced by industry.Publishing SCS Research: The by Traeger et al. that academic journals should never publish anything with industry ties – in SCS or any field of medicine.Reality of SCS Funding: Understanding the intricacies of device research funding as well as the limitations of funding outside of industry (e.g., government funding) and contextualizing the paucity of placebo- or sham-controlled studies.Ethics in Academic Societies: Clarifying the policies surrounding conflicts of interest amongst academic societies.Debunking Hara et al.: Understanding the methodologic flaws of the Hara et al. study of SCS for Chronic Radicular Pain After Lumbar Spine Surgery.Listen in as we navigate these complex waters, aiming to provide a balanced perspective on the interplay between industry funding, scientific research, and clinical practice in pain medicine. This episode is a must-listen for anyone looking to understand the multifaceted nature of pain medicine in today's healthcare landscape.CORRECTION (11:10-11:50): SCS for FDA requires a premarket approval (PMA). There is no need for clinical data if it is possible to prove equivalence. For external powered devices where RF is the predicate device, FDA 510k pathway is required.
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, January 19, 2024. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Onward began a study of its neurostimulation technology for addressing post-spinal cord injury hemodynamic instability. Fast Five hosts Sean Whooley and Danielle Kirsh look at what this study aims to accomplish and discuss how Onward applies its technology in a variety of ways. The FDA approved expanded labeling for the Abbott Proclaim neurostimulation system, allowing those implanted with the device to receive full-body MRI scans. The hosts look into the importance of MRI compatibility and how the Proclaim system works. Orthofix partnered with MRIguidance, combining surgical navigation technology with innovative software. Find out what this partnership entails and how the companies feel about their latest development. Medtronic reported positive data for multiple spinal cord stimulation technologies. Hear about some of the key results from the medtech giant's studies presented at the North American Neuromodulation Society (NANS) annual meeting in Las Vegas. Abbott announced the first procedures completed with its Volt pulsed field ablation system. Whooley and Kirsh take a look at the latest entry into the crowded PFA space and examine what could potentially set Abbott's new technology apart.
Industry tries to do what it can to keep the secret that these devices just don't work very well.
#223Spinal cord stimulation has, for the first time, been used to improve the mobility of someone with Parkinson's Disease. Marc, who has battled the condition for 30 years, once fell five to six times daily, but now is able to walk kilometres per day thanks to an array of electrodes that stimulate the movement-related neurons in his spine. Though it was successful for Marc, the treatment is also highly customised and more research is needed before it might benefit people more broadly. In the world of synthetic biology, an international team has crafted a yeast cell with half its DNA manufactured in a lab, marking a significant step in our ability to rewrite and alter complex genomes. While yeast is already used to create useful substances such as beer and insulin, synthetic yeasts could be engineered to create an even wider variety of molecules more easily. Why yeast might be just the beginning for synthetic organisms.Can the secret to affordable, clean energy have been in the ocean all this time? Engineers are bringing a 140-year-old idea back to life, with the aim of harnessing the massive temperature difference between warm surface water and cold, deep sea water. A process known as Ocean Thermal Energy Conversion (OTEC) was originally proposed in the 19th century and is now being tested in some island nations. How this sustainable method works and the obstacles to its widespread adoption.New evolutionary research shows that crabs evolved to leave the ocean up to 17 different times in the 230 million years since they arose. What these crustaceans' remarkable evolutionary flexibility might reveal about adaptability across the animal kingdom.Plus: Using tiny microphones to record happy rat squeaks, a breakthrough in underwater radio communication and a smashing fact about left-handed badminton players. Hosts Christie Taylor and Chelsea Whyte discuss all of this with guests Michael Le Page, James Dinneen and Alexandra Thompson. To read more about these stories, visit newscientist.com. Hosted on Acast. See acast.com/privacy for more information.
Have you ever wondered how the future of neurorehabilitation will look like? Step into this future with our latest episode on the BCI Award Neurocareers podcast series. Explore the forefront of neurorehabilitation through the groundbreaking project that earned a nomination for the prestigious International BCI Award in 2021: "Application of brain-computer interface based on visuomotor transformation to controlling neurorehabilitation robot and transcutaneous spinal cord-stimulation." Dive into the heart of neuromodulation and neuronal repair after spinal cord injuries, where every aspect of neural recovery is meticulously considered. This project is a beacon of hope for those seeking the restoration of motor functions through advanced technologies. The team behind it is a symphony of expertise featuring Dr. Igor Lavrov, an Assistant Professor in the Department of Neurology and Biomedical Engineering at Mayo Clinic, pioneering new dimensions in neurology. Alongside him stands the visionary Dr. Mikhail Lebedev, a leading world figure in Neurophysiology and Brain-Computer Interfaces, illuminating the path toward innovative solutions. Dr. Carlos Alberto Cuellar, a relentless advocate for neurotechnologies from Universidad Anáhuac México, and Ilia Borishchev, a spacecraft engineer turned entrepreneur and the founder of VIBRAINT company in Canada, complete this stellar team that spans across borders to shape the future of neurorehabilitation. In this riveting episode, we unveil the intricate details of their groundbreaking project that harnesses the power of brain-computer interfaces for controlling neurorehabilitation robots and transcutaneous spinal-cord stimulation. But that's not all! Tune in to gain insights straight from the minds behind this remarkable project as they generously share their wisdom on crafting a successful BCI Award submission. Join us on this captivating journey as we unravel the inspirations, innovations, and transformative impact of this outstanding project. Get ready to explore the boundless possibilities at the intersection of neurorehabilitation, brain-computer interfaces, and visionary collaboration. Tune in now and be part of the neurotech revolution! About the Podcast Guests: Igor Lavrov, MD, PhD - An Assistant Professor at the Department of Neurology and the Department of Biomedical Engineering at Mayo Clinic. Dr. Lavrov was trained in medicine (neurology) and neuroscience. With a career spanning over two decades, he has played an integral role in both participating in and directing a multitude of research endeavors. Dr. Lavrov's work has encompassed a comprehensive study of spinal cord neuromodulation, carried out across various animal models and clinical trials. His extensive experience has uniquely positioned him to delve into the intricate world of neuronal circuits, their modulation, reorganization, and repair following traumatic injuries, with a particular emphasis on spinal cord stimulation and regenerative therapies. LinkedIn: https://www.linkedin.com/in/lavrovi/ ResearchGate: https://www.researchgate.net/profile/Igor-Lavrov Mikhail Lebedev, PhD - a renowned figure in the fields of Neurophysiology and Brain-Computer Interfaces. With a remarkable track record of over 100 publications, his extensive contributions have significantly shaped the landscape of neuroscientific research. These contributions have led to innovative solutions in decoding brain activity and translating it into actionable commands for robotic and prosthetic devices. Dr. Lebedev's groundbreaking studies involving nonhuman primates have provided profound insights. His work has showcased the direct control of prosthetic and virtual limb movements through cortical activity recorded with multichannel implants. Furthermore, his research has demonstrated the creation of artificial tactile sensations through the precise delivery of electrical microstimulations within the somatosensory cortex. Dr. Lebedev's illustrious journey has encompassed research institutions spanning from the Institute for Problems of Information Transmission in Moscow to the University of Tennessee in Memphis, SISSA in Trieste, Italy, NIMH in Bethesda, Maryland, later in Duke University in Durham, North Carolina, and in National Research University - Higher School of Economics in Moscow. LinkedIn: https://www.linkedin.com/in/mikhail-lebedev-1843b210/ ResearchGate: https://www.researchgate.net/profile/Mikhail-Lebedev-8 Carlos Alberto Cuellar, PhD - A forward-thinking scientist at the forefront of neurotechnologies, Dr. Cuellar's research encompasses brain-computer interfaces, neural prosthetics, and neuromodulation techniques. He is affiliated with Universidad Anáhuac México, contributing to international collaborations that drive advancements in the field. LinkedIn: https://www.linkedin.com/in/carlos-alberto-cuellar-ramos-172846116/ Webpage: https://www.anahuac.mx/mexico/EscuelasyFacultades/cienciasdeldeporte/investigacion/dr-en-c-carlos-cuellar-ramos email: carlos.cuellarra@anahuac.mx Ilia Borishchev - An extraordinary individual who transitioned from being a visionary spacecraft engineer to an entrepreneur in the neurotechnology domain. As the founder of VIBRAINT, a pioneering company in Canada, Ilia's commitment to innovation and technology-driven solutions has catalyzed groundbreaking developments in the intersection of neurorehabilitation and advanced neurotechnologies. LinkedIn: https://www.linkedin.com/in/iliaborishchev/ VIBRAINT: https://vibraint.ai/ For more information about the remarkable work and contributions of our guests, please visit their respective web pages and connect with them on LinkedIn. About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a neuroscience educator, research consultant, and career coach for students and recent graduates in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities facing students in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume and cover letter development, and interview preparation Access to a network of professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news
Spinal cord stimulation has, for the first time, been shown to help two people with upper body paralysis due to stroke regain some arm movement. To find out how this groundbreaking technology works, New Scientist health reporter Grace Wade speaks to two researchers who helped conduct this research - Nikhil Verma at Carnegie Mellon University in Pittsburgh, Pennsylvania and Erynn Sorensen at the University of Pittsburgh.She also speaks to Heather, one of the study's participants, who explains the emotional moment when she was able to open and close her hand for the first time in a decade.To read about subjects like this and much more, you can subscribe to New Scientist magazine at newscientist.com. Hosted on Acast. See acast.com/privacy for more information.
In Episode 51, we were joined by Marc Powell to speak about the ground-breaking neuro-technology he and his team at Reach Neuro are working on to restore arm and hand movement in patients who survived severe strokes. Globally, every fourth adult over the age of 25 will suffer a stroke in their lifetime, and 75% of those people will have lasting deficits in motor control of their arm and hand, severely limiting their physical autonomy. In April 2023, the FDA granted breakthrough device designation for Reach Neuro's Avantis, a platform that delivers small electrical impulses to the spinal cord to restore shoulder, arm, and hand movement to post chronic stoke patients. The Avantis system is built to restore a patient's ability to control movement directly, giving them not only immediate relief but also allowing it to be possible for them to return to therapy. Early evidence has shown the effectiveness of the system in patients with chronic stroke up to 9 years poststroke, outside of the 6 month window where existing therapies are typically used. Connect with Marc on Twitter: @marcppowell Visit the Reach Neuro Website: https://www.reachneuro.com/ Show Credits: Music intro credit to Jake Dansereau, connect at JAKEEZo on Soundcloud @user-257386777. Our intro welcome is the voice of Caroline Goggin, a stroke survivor and our first podcast guest! Please listen to her inspiring story on Episode 2 of the podcast. Until next time, be sure to give the show a like and share, +follow and connect with us on social or contact us to support us as a show sponsor or become a guest on the Know Stroke Podcast. Visit our new website to apply here: https://www.knowstrokepod.com/ Connect with Us and Share our Show on Social: Website | Linkedin | Twitter | YouTube | Facebook
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.30.534835v1?rss=1 Authors: Bryson, N. K., Lombardi, L., Hawthorn, R., Fei, J., Keesey, R., Peiffer, J. D., Seanez, I. Abstract: Objective. Transcutaneous spinal cord stimulation (tSCS) has been gaining momentum as a non-invasive rehabilitation approach to restore movement to paralyzed muscles after spinal cord injury (SCI). However, its low selectivity limits the types of movements that can be enabled and, thus, its potential applications in rehabilitation. Approach. In this cross-over study design, we investigated whether muscle recruitment selectivity of individual muscles could be enhanced by multielectrode configurations of tSCS in 16 neurologically intact individuals. We hypothesized that due to the segmental innervation of lower limb muscles, we could identify muscle-specific optimal stimulation locations that would enable improved recruitment selectivity over conventional tSCS. We elicited leg muscle responses by delivering biphasic pulses of electrical stimulation to the lumbosacral enlargement using conventional and multielectrode tSCS. Results. Analysis of recruitment curve responses confirmed that multielectrode configurations could improve the rostrocaudal and lateral selectivity of tSCS. To investigate whether motor responses elicited by spatially selective tSCS were mediated by posterior root-muscle reflexes, each stimulation event was a paired pulse with a conditioning-test interval of 33.3 ms. Muscle responses to the second stimulation pulse were significantly suppressed, a characteristic of post-activation depression suggesting that spatially selective tSCS recruits proprioceptive fibers that reflexively activate muscle-specific motor neurons in the spinal cord. Moreover, the combination of leg muscle recruitment probability and segmental innervation maps revealed a stereotypical spinal activation map in congruence with each electrode's position. Significance. Improvements in muscle recruitment selectivity could be essential for the effective translation into stimulation protocols that selectively enhance single-joint movements in neurorehabilitation. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Cochrane Library's recently published article questioning the clinical benefit of spinal cord stimulation for low back pain has stirred controversy throughout the pain medicine community. In response to these findings, we sat down with neuromodulation specialists & Pain Medicine journal editorial board members, Zachary McCormick, MD, and Nathaniel M. Schuster, MD, to offer our in-depth reaction and analysis of the March 2023 report. In this episode of the Pain Matters Podcast, host Shravani Durbhakula, MD, MPH, MBA, and co-host @Mustafa Broachwala, DO, are joined by Zachary McCormick, MD, Chief of Spine and Musculoskeletal Medicine at the University of Utah & Nathaniel M. Schuster, MD, Associate Clinical Director of the Center for Pain Medicine at UC San Diego. We are live in-person at AAPM's 39th Annual Meeting in Fort Lauderdale, FL, to discuss the implications of the Cochrane Library's spinal cord stimulation review and what it means for providers and patients. Additionally, David Caraway, MD, PhD, Chief Medical Officer of Nevro Corp., calls in to give his expert insight on the controversial inclusion and exclusion of certain studies and how this impacts the conclusions of the review. Lastly, we go to Vwaire Orhurhu MD, MPH, author of a widely-read letter to the editor published in JAMA in response to the Hara et al. study, which is critical to the Cochrane Library Review's conclusions.Tune in to discover:In-depth scientific analysis and reaction to the curious findings, generalizations, and omissions from the reviewHow to interpret the Cochrane Library's recent findings and what they actually might mean for clinical practice. What this review means for patient care and the future of SCS in pain medicine Reference: Traeger AC, Gilbert SE, Harris IA, Maher CG. Spinal cord stimulation for low back pain. Cochrane Database of Systematic Reviews 2023, Issue 3. Art. No.: CD014789. DOI: 10.1002/14651858.CD014789.pub2. Accessed 29 March 2023.
The effect of artificial sweeteners, restoring arm mobility in stroke and accident patients, curing HIV, and a new way to monitor glucose.See omnystudio.com/listener for privacy information.
In this episode, we speak with Dr. Aaron Phillips about the paper titled "Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury" published in 2021 in the journal Nature (doi: 10.1038/s41586-020-03180-w).
In this episode, we speak with Dr. Aaron Phillips about the paper titled "Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury" published in 2021 in the journal Nature (doi: 10.1038/s41586-020-03180-w).
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.18.528981v1?rss=1 Authors: Sharma, M., Bhaskar, V., Yang, L., FallahRad, M., Gebodh, N., Zhang, T., Esteller, R., Martin, J., Bikson, M. Abstract: Spinal cord stimulation (SCS) evokes fast epidural Evoked Compound Action Potential (ECAPs) that represent activity of dorsal column axons, but not necessarily a spinal circuit response. Using a multimodal approach, we identified and characterized a delayed and slower potential evoked by SCS that reflects synaptic activity within the spinal cord. Anesthetized female Sprague Dawley rats were implanted with an epidural SCS lead, epidural motor cortex stimulation electrodes, an epidural spinal cord recoding lead, an intraspinal penetrating recording electrode array, and intramuscular electromyography (EMG) electrodes in the hindlimb and back. We stimulated the motor cortex or the epidural spinal cord and recorded epidural, intraspinal, and EMG responses. SCS pulses produced characteristic propagating ECAPs (composed of P1, N1, and P2 waves with latencies less than 2 ms) and an additional wave (S1) starting after the N2. We verified the S1-wave was not a stimulation artifact and was not a reflection of hindlimb/back EMG. The S1-wave has a distinct stimulation-intensity dose response and spatial profile compared to ECAPs. CNQX (a selective competitive antagonist of AMPA receptors) significantly diminished the S1-wave, but not ECAPs. Furthermore, cortical stimulation, which did not evoke ECAPs, produced epidurally detectable and CNQX-sensitive responses at the same spinal sites, confirming epidural recording of an evoked synaptic response. Finally, applying 50 Hz SCS resulted in dampening of ESAPs, but not ECAPs. Therefore, we hypothesize that the S1-wave is synaptic in origin, and we term the S1-wave type responses: Evoked Synaptic Activity Potentials (ESAPs). The identification and characterization of epidurally recorded ESAPs from the dorsal horn may elucidate SCS mechanisms. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Claim CME The CE experience for this Podcast is powered by CMEfy - click here to reflect and earn credits: https://earnc.me/tn70Yk Dr. Rosenblum discuss a challenging case and reviews the pathology, treatment and evidence for interventional pain in the the treatment of Post Herpetic Neuralgia. Discussed in this podcast: Intrathecal injection of methylprednisolone Dorsal Root Ganglion Paraveterbral Nerve Block Stellate Ganglion Block Spinal Cord Stimulation Botulinum Toxin Injection And more! Course Calendar Ultrasound Guided Regional Anesthesia and Pain Medicine Tamarindo, Puerto Rico- Feb. 10, 2023 Ultrasound Guided Regional Anesthesia and Pain Medicine Tamarindo, Costa Rica- Feb. 19, 2023 Ultrasound Guided Regional Anesthesia and Pain Medicine NYC- March 11, 2023 Ultrasound Guided Regional Anesthesia and Pain Medicine NYC- April 22, 2023 Regenerative Pain Medicine Course NYC- May 13 Pain Management Board Review/Refresher Course/ Ultrasound Training NYC- June 9-11, 2023 References Lin, Chia-Shiang, et al. "Interventional treatments for postherpetic neuralgia: a systematic review." Pain physician22.3 (2019): 209. https://www.painphysicianjournal.com/current/pdf?article=NjMwMg%3D%3D&journal=120
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.01.10.523167v1?rss=1 Authors: Sagalajev, B., Zhang, T., Abdollahi, N., Yousefpour, N., Medlock, L., Al-Basha, D., Ribeiro-da-Silva, A., Esteller, R., Ratte, S., Prescott, S. A. Abstract: Spinal cord stimulation (SCS) reduces chronic pain. Conventional (40-60 Hz) SCS engages spinal inhibitory mechanisms by activating low-threshold mechanoreceptive afferents with axons in the dorsal columns (DCs). But activating DC axons typically causes a buzzing sensation (paresthesia) that can be uncomfortable. Kilohertz-frequency (1-10 kHz) SCS produces analgesia without paresthesia and is thought, therefore, not to activate DC axons, leaving its mechanism unclear. Here we show in rats that kilohertz-frequency SCS activates DC axons but causes them to spike less synchronously than conventional SCS. Spikes desynchronize because axons entrain irregularly when stimulated at intervals shorter than their refractory period, a phenomenon we call overdrive desynchronization. Effects of overdrive desynchronization on evoked compound action potentials were verified in simulations, rats, pigs, and a chronic pain patient. Whereas synchronous spiking in DC axons is necessary for paresthesia, asynchronous spiking is sufficient to produce analgesia. Asynchronous activation of DC axons thus produces paresthesia-free analgesia. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
In this week's podcast, Neurology Today's editor-in-chief discusses a comparison of spinal cord stimulation with medical management for chronic pain, earlier brain aging in Black people, and the pros/cons of working for teleneurology companies.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.12.26.521912v1?rss=1 Authors: Slack, J. C., Zeiser, S. L., Yadav, A. P. Abstract: Sensory feedback is critical for effectively controlling brain-machine interfaces (BMIs) and neuroprosthetic devices. Spinal cord stimulation (SCS) is proposed as a technique to induce artificial sensory perceptions in rodents, monkeys, and humans. However, to realize the full potential of SCS as a sensory neuroprosthetic technology, a better understanding of the effect of SCS pulse train parameter changes on sensory detection and discrimination thresholds is necessary. Here we investigated whether stimulation periodicity impacts rat's ability to detect and discriminate SCS-induced perceptions at different frequencies. By varying the coefficient of variation (CV) of interstimulus pulse interval, we showed that at lower frequencies, rats could detect highly aperiodic SCS pulse trains at lower amplitudes (i.e., decreased detection thresholds). Furthermore, rats learned to discriminate stimuli with subtle differences in periodicity, and the just-noticeable differences (JNDs) from a highly aperiodic stimulus were smaller than those from a periodic stimulus. These results demonstrate that the temporal structure of an SCS pulse train is an integral parameter for modulating sensory feedback in neuroprosthetic applications. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Want to be on the show or have questions? Email Me! matt.custodero@gmail.com Sources: https://pubmed.ncbi.nlm.nih.gov/31870766/ https://www.frontiersin.org/articles/10.3389/fnins.2017.00339/full https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359972/pdf/PAPR-21-680.pdf https://jamanetwork.com/journals/jamaneurology/article-abstract/2788004 https://www.prnewswire.com/news-releases/publication-of-two-year-evoke-double-blind-randomized-controlled-trial-results-in-jama-neurology-demonstrate-sustained-superiority-of-evoke-closed-loop-over-open-loop-spinal-cord-stimulation-301456813.html#:~:text=Significant%20findings%20of%20Evoke%20ECAP,84%25%20and%2050%25%2C%20respectively https://www.saludamedical.com/us/evidence For Gate Control Theory: https://www.physio-pedia.com/Gate_Control_Theory_of_Pain#:~:text=The%20Gate%20Control%20Theory%20of,be%20let%20through%20or%20restricted.
Neurostimulation is advancing in exciting ways. One such innovation is called high frequency spinal cord stimulation which does not cause a tingling sensation. In fact, it just replaces the pain, with pain relief. Studies suggest that it may better control chronic low back pain too. Robin describes how this new spinal cord stimulator changed her […]
Neurostimulation is advancing in exciting ways. One such innovation is called high frequency spinal cord stimulation which does not cause a tingling sensation. In fact, it just replaces the pain, with pain relief. Studies suggest that it may better control chronic low back pain too. Robin describes how this new spinal cord stimulator changed her […]
Neurostimulation is advancing in exciting ways. One such innovation is called high frequency spinal cord stimulation which does not cause a tingling sensation. In fact, it just replaces the pain, with pain relief. Studies suggest that it may better control chronic low back pain too. Robin describes how this new spinal cord stimulator changed her […]
Neurostimulation is advancing in exciting ways. One such innovation is called high frequency spinal cord stimulation which does not cause a tingling sensation. In fact, it just replaces the pain, with pain relief. Studies suggest that it may better control chronic low back pain too. Robin describes how this new spinal cord stimulator changed her […]
Physicians strive to find ways for their patients to live healthy, active lifestyles, and that is what attracted Dr. Dave Eichman to the specialty of spinal cord stimulation. In this episode of Back Talk, host Dr. Sanjiv Lakhia and his guest, Dr. Eichman, cover what makes a patient a good candidate for the treatment, what to expect from it, and some potential pitfalls. “The unique ability to test the device before committing can help patients feel more confident in their choice. “[Once] you've had the surgery done, there's no going back. But with the stimulator, there's a five-to-seven day trial period where you come in, like you're gonna have an injection performed,” Dr. Eichman says while explaining a unique aspect of this treatment. “You just get to try it out, see if you can walk further, stand longer, sleep better, use less pain medicine. Are you comfortable with it?” The technology behind spinal cord stimulation has made significant progress since it first became available almost 50 years ago. In the past ten years alone there have been major improvements in the therapeutic modality of the device, so patients have more choices in what the treatment feels like to them. The devices are also now MRI-friendly, giving patients more imaging choices than they traditionally had if they had chosen to pursue this treatment. Tune in to this episode of Back Talk to hear how spinal cord stimulation can improve the lives of patients living with recurring nerve pain.
Machine Medicine Interview Series hosted by Dr Jonathan O'Keeffe with Dr Krishnan Chakravarthy. Where does SCS (Spinal Cord Stimulation) come from? Transcript for interview highlight: https://machinemedicine.com/interview-series/optimizing-electrical-dose-in-spinal-cord-stimulation/ Find out more topics: https://machinemedicine.com/interview-series/
In this episode, Ayesha discussed Elon Musk's recent revelation that in addition to fasting, he also used Novo Nordisk's weight loss drug Wegovy to help him get “lean and fit.” In response to a question on Twitter, Musk disclosed that both fasting and Wegovy were his secrets to his recent weight loss. Musk is not affiliated with Novo so his endorsement of the drug came as a surprise, and is also problematic according to some. Hear more about the story in this episode.The editorial team also learned about the FDA approval of Nevro Corp's AI-based spinal cord stimulation (SCS) system for the treatment of chronic pain. Nevro says its Senza HFX iQ system is the first and only AI-based SCS system that personalizes care by “learning from patients.” The implantable device delivers neurostimulation via the company's proprietary high frequency pulse technology that has been evaluated in more than 90,000 patients. Read the full articles here:Elon Musk Reveals Weight Loss Injection Wegovy Helped Him Get Lean and FitNevro's AI-Based Spinal Cord Stimulation Device for Chronic Pain Receives FDA ApprovalFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the October 18, 2022 issue.
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
Dan Brounstein is Chief Strategy Officer at Saluda Medical where he is using his 15 years of Spinal Chord Stimulator experience to help deliver closed-loop pain relief directly to the spinal cord. ***This podcast is sponsored by Iris Biomedical, check out their Neurotech Startup Services here*** Top 3 Takeaways: "We're stimulating with milliamps and we're trying to measure in microvolts, and we always use the analogy trying to listen to a pin drop next to a shotgun shot" "There's a lot of literature on loss of efficacy? It's just a therapy issue. When you deliver open-loop therapies blind across a neural target, you're ultimately going to create, over-stimulation in a lot of times under stimulation. On top of that, over time things change" "Patients come in between four and five times a year on average in perpetuity with open loop systems" 0:45 " Do you want to introduce yourself and the company better than I just did?" 6:00 "Your guys' device reprograms on its own? And then what signals does it take in and how does it change the stimulation patterns based on that?" 9:00 Iris Biomedical ad sponsorship 9:45 "What is your input and output for your guys' device?" 11:45 "In February of 2023, you guys got FDA approval for this. Do you wanna talk a little bit about this?" 14:15 "Is it like 5% better than open loop or is that something that's gonna be coming out published later?" 17:00 "Is there another indication?" 18:15 "The last I guess seven years for you has been very exciting. Is there anything on the horizon for the next seven years?" 20:15 "You guys have 300 people and have raised 200 million. What's it like working in such a big company" 22:45 "Is it getting too big for you?" 23:45 "What advice do you have for people in your situation?" 26:00 "Is there anything that we didn't talk about that you wanted to mention?"
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.19.508432v1?rss=1 Authors: Rees, B., Borda, E., Nicolelis, M. A., Yadav, A. P. Abstract: Dorsal column stimulation (DCS) of the spinal cord is emerging as a promising new technology for the treatment of Parkinson's disease (PD). However, the mechanisms underlying its therapeutic effect on PD symptoms are not fully understood. Here we demonstrate a closed-loop DCS (CLDCS) paradigm - a substantial advancement from previously tested continuous high-frequency DCS - in a bilateral intrastriatal 6-hydroxydopamine (6-ohda) rodent model of PD. Firstly, CLDCS performed significantly better than continuous open-loop DCS in ameliorating motor symptoms of PD. Secondly, the application of CLDCS triggered by corticostriatal beta frequency oscillations created a pro-locomotion brain state that reduced akinesia. Finally, CLDCS was better at disrupting beta oscillations in the corticostriatal areas and achieved it with lesser overall charge delivery than continuous open-loop stimulation. These results indicate that CLDCS is remarkably better than traditional spinal cord stimulation methods and has the potential to be highly effective in treating PD symptoms. We envision that the CLDCS approach can be beneficial in the treatment of other neurological disorders which showcase similar pathological neuronal oscillations. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.19.508432v1?rss=1 Authors: Rees, B., Borda, E., Nicolelis, M. A., Yadav, A. P. Abstract: Dorsal column stimulation (DCS) of the spinal cord is emerging as a promising new technology for the treatment of Parkinson's disease (PD). However, the mechanisms underlying its therapeutic effect on PD symptoms are not fully understood. Here we demonstrate a closed-loop DCS (CLDCS) paradigm - a substantial advancement from previously tested continuous high-frequency DCS - in a bilateral intrastriatal 6-hydroxydopamine (6-ohda) rodent model of PD. Firstly, CLDCS performed significantly better than continuous open-loop DCS in ameliorating motor symptoms of PD. Secondly, the application of CLDCS triggered by corticostriatal beta frequency oscillations created a pro-locomotion brain state that reduced akinesia. Finally, CLDCS was better at disrupting beta oscillations in the corticostriatal areas and achieved it with lesser overall charge delivery than continuous open-loop stimulation. These results indicate that CLDCS is remarkably better than traditional spinal cord stimulation methods and has the potential to be highly effective in treating PD symptoms. We envision that the CLDCS approach can be beneficial in the treatment of other neurological disorders which showcase similar pathological neuronal oscillations. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.06.506783v1?rss=1 Authors: Dalrymple, A. N., Hooper, C. A., Kuriakose, M. G., Capogrosso, M., Weber, D. J. Abstract: Spinal cord neuromodulation has gained much attention for demonstrating improved motor recovery in people with spinal cord injury, motivating the development of clinically applicable technologies. Among them, transcutaneous spinal cord stimulation (tSCS) is attractive because of its non-invasive profile. Many tSCS studies employ a high-frequency (10 kHz) carrier, which has been reported to reduce stimulation discomfort. However, these claims have come under scrutiny in recent years. The purpose of this study was to determine whether high-frequency tSCS is more comfortable at therapeutic amplitudes, which evoke posterior root-muscle (PRM) reflexes. In 16 neurologically intact participants, tSCS was delivered using a 1-ms long monophasic pulse with and without a high-frequency carrier. Stimulation amplitude and pulse duration were varied and PRM reflexes were recorded from the soleus, gastrocnemius, and tibialis anterior muscles. Participants rated their discomfort during stimulation from 0-10 at PRM reflex threshold. At PRM reflex threshold, high-frequency stimulation (0.87 {+/-} 0.2) was equally comfortable as conventional stimulation (1.03 {+/-} 0.18) but required approximately double the charge to evoke the PRM reflex (conventional: 32.4 {+/-} 9.2 C; high-frequency: 62.5 {+/-} 11.1 C). Strength-duration curves for high-frequency stimulation had a rheobase that was 4.8X greater and a chronaxie that was 5.7X narrower than the conventional monophasic pulse, indicating that high-frequency stimulation was less efficient in recruiting neural activity in spinal roots. High-frequency tSCS is equally as comfortable as conventional stimulation at amplitudes required to stimulate spinal dorsal roots. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer
In this week's podcast, Neurology Today's editor-in-chief discusses spinal cord stimulation for painful diabetic neuropathy, the Roe v. Wade reversal and neurology, and initiatives to diversify the neurology pipeline.
In this episode, we’ll be hosting the accomplished Dr. Christopher Gay. Dr. Gay is an accomplished, board-certified anesthesiologist and interventional pain specialist in Anchorage, AK. Originally from North Carolina, he attended Duke University for his undergraduate work and subsequently earned his medical degree from the University of North Carolina at Chapel Hill. After completing his residency and fellowship training at New York’s Presbyterian Hospital at Columbia University, he practiced as part of a large pain practice in Northern Virginia before moving to Alaska in March of 2015 to found the Alaska Center for Pain Relief Inc. He continues to enjoy living in the Pacific Northwest with his family. Find Alaska Center for Pain Relief Online: Alaska Center for Pain Relief's Website Cool stuff discussed during the episode that you should further explore: Spinal Cord Stimulation – Cutting edge service that Dr. Gay’s practice offers Medical Practice Loans – Dr. Gay shared his experience when he was exploring the community where he could open a practice of how a banker stopped by his hotel to introduce themselves and develop a relationship with him. It’s important that you shop rates and compare options. Knocking Doors – Dr. Gay spoke about the importance of getting out there and meeting providers or potential patients, may it be out at actual medical offices or in the community at events hosted by medical organizations such as American Cancer Society, etc. Book: Thinking Fast and Slow by Daniel Kahneman Book: Can’t Hurt Me: Master Your Mind and Defy the Odds by David Goggins Tool: Upwork – A website that Dr. Gay uses to identify freelancers for the business Quote: “Good, better, best, never let it rest, until your good turns to better, and better turns to best” – Teacher from Dr. Gay’s past Quote: “Don’t be afraid to fail, but always have a contingency plan” – Dr. Gay
Hi! I'm Dr. Myrdalis Diaz-Ramirez. And, this is Episode #22!Today, we have a very special guest, my dear friend, and great Dr. Nilesh Patel!Dr. Patel is actually Vice-President of Medical Affairs at Boston Scientific for Spinal Cord Stimulation. We have a great conversation with Dr. Patel, about working for the private sector and preparing to be physicians who are the private equity. There are many, many great tips and insight in this episode. Don't miss it! Enjoy!Thank you for joining us this week!----------------------------------------------------------------------------------------------------Follow Dr. Myrdalis Diaz at these links: Website: drmyrdalisdiaz.comPodcast: Design Your Physician LifeLinkedin: Myrdalis Diaz-Ramirez Facebook: Dr. Myrdalis Diaz-Ramirez
On this episode of Premier Pain Talk, host Dr. Michael Danko talks with Dr. Michael Fishman. He is a fantastic pain physician out of the Greater Philadelphia area. They are discussing spinal cord stimulation and some of the new horizons coming with it as well as digital health and data capturing and potentially new options for pain therapy down the road. Tune in! Episode Highlights: Dr. Fishman went to medical school at Jefferson Medical College, and he developed an interest in anesthesia, ENT, and neck surgery. And at the end of the day, he ended up as a surgery resident at a program outside of Philadelphia. During his time working with the anesthesiologist at the hospital, Dr. Fishman ultimately found that perhaps there is a better use of his interests to look after patients after surgery and around their surgeries. Dr. Fishman's clinic is like a lab where we get the opportunity to think of new ways to help people and ways to get patients the right treatment at the right time. One of the therapies that gets Dr. Danko super excited and makes it not feel like work sometimes, is something called a spinal cord stimulator. It is an implantable device and has been around for many years. Spinal stimulation in Dr. Danko's mind has gone through now maybe even more advancements than cell phone technology or other technology of any type. What is ‘The Gate Control Theory On Chronic Pain'? Tonic stimulation is something that people should be familiar with, and it's a buzzing electrical sensation or maybe tapping and pulsing. They talk about how it had previously been practiced. Over the last few years, there has been a fine tuning of the electrical signals that are being passed in the spinal cord. If you talk to a bunch of different pain doctors or different people from industry, you are going to get a bunch of different answers for advancements with changes in the way the electricity is being delivered through devices. There is a psychological and social component that is also important to understand when you think about why pain doctors do what they are doing; That is why when they do apply therapies like simulation, it's important to understand biologically why also. For humans, isolation, depression, anxiety, status, etc all go in the same path with pain; But we can change the pain experience for the better or for the worse. 3 Key Points: One thing about Yale Haven hospital that everybody should know is it is smack dab in the middle at the junction of I-95 I-91, which means that it is a super busy hospital and gets most of the trauma in the state. DTM therapy is fantastic and the science behind how to fine-tune that therapy is very durable. Getting patients the right treatment is the job of a pain doctor, but it's also about the right timing being understood and the circumstances/ context for each person to make the best version of themselves that they can be, says Fishman. Resources Mentioned: https://premierpaintreatment.com/ https://www.facebook.com/PremierPainTreatment/ https://www.christianhospital.org/painfree https://celerihealth.com/
Machine Medicine Interview Series hosted by Dr Jonathan O'Keeffe with Dr Georgios Matis. What is peripheral vascular disease and how can it be treated using spinal cord stimulation? Transcript for interview highlight: https://machinemedicine.com/interview-series/spinal-cord-stimulation-for-peripheral-vascular-diseases/ Find out more topics: https://machinemedicine.com/interview-series/
Dr. Erika Peterson discusses her abstract, "Durability of 10-kHz Spinal Cord Stimulation for Painful Diabetic Neuropathy: 18-Month Multicenter Randomized Controlled Trial Results" Show references: https://index.mirasmart.com/aan2022/PDFfiles/AAN2022-003466.html
On this episode of Premier Pain Talk, host Dr. Michael Danko talks with Dr. Michael Fishman. He is a fantastic pain physician of the Greater Philadelphia area. They are discussing spinal cord stimulation and some of the new horizons coming with it as well as digital health and data capturing and potentially new options for pain therapy down the road. Episode Highlights: Dr. Fishman went to medical school at Jefferson Medical College, and he developed an interest in anesthesia, ENT, and neck surgery. And at the end of the day, he ended up as a surgery resident at a program outside of Philadelphia. During his time working with the anesthesiologist at the hospital, Dr. Fishman ultimately found that perhaps there is a better use of his interests to look after patients after surgery and around their surgeries. Dr. Fishman's clinic is like a lab where we get the opportunity to think of new ways to help people and ways to get patients the right treatment at the right time. One of the therapies that gets Dr. Danko super excited and makes it not feel like work sometimes, is something called a spinal cord stimulator. It is an implantable device and has been around for many years. Spinal stimulation in Dr. Danko's mind has gone through now maybe even more advancements than cell phone technology or other technology of any type. What is ‘The Gate Control Theory On Chronic Pain'? Tonic stimulation is something that people should be familiar with, and it's a buzzing electrical sensation or maybe tapping and pulsing. They talk about how it had previously been practiced. Over the last few years, there has been a fine tuning of the electrical signals that are being passed in the spinal cord. If you talk to a bunch of different pain doctors or different people from industry, you are going to get a bunch of different answers for advancements with changes in the way the electricity is being delivered through devices. There is a psychological and social component that is also important to understand when you think about why pain doctors do what they are doing; That is why when they do apply therapies like simulation, it's important to understand biologically why also. For humans, isolation, depression, anxiety, status, etc all go in the same path with pain; But we can change the pain experience for the better or for the worse. 3 Key Points: One thing about Yale Haven hospital that everybody should know is it is smack dab in the middle at the junction of I-95 I-91, which means that it is a super busy hospital and gets most of the trauma in the state. DTM therapy is fantastic and the science behind how to fine-tune that therapy is very durable. Getting patients the right treatment is the job of a pain doctor, but it's also about the right timing being understood and the circumstances/ context for each person to make the best version of themselves that they can be, says Fishman. Resources Mentioned: https://premierpaintreatment.com/ https://www.facebook.com/PremierPainTreatment/ https://www.christianhospital.org/painfree https://celerihealth.com/
Exploring The Spinal Cord Stimulation Devices Market by Informa
What in the world is a Bioelectronic Medicine? As promised, link to schema below
Dr. Ebell and Dr. Wilkes discuss the POEM titled ' High-frequency spinal cord stimulation improves pain in patients with refractory painful diabetic neuropathy '
"Closed Loop Spinal Cord Stimulation," by Corey W. Hunter, MD, Executive Director, Ainsworth Institute of Pain Management, New York, New York; and Jason Pope, MD, President, Chief Executive Officer, Evolve Restorative Center, Santa Rosa, California. From ASRA News, August 2021. See original article at www.asra.com/asra-news for figures and references. This material is copyrighted.
Machine Medicine Interview Series hosted by Dr Jonathan O'Keeffe with Dr Tim Deer How closed-loop spinal cord stimulation and data-driven decisions in neuromodulation can benefit patients with pain. Transcript for interview highlight: https://machinemedicine.com/interview-series/closed-loop-spinal-cord-stimulation/ Find out more topics: https://machinemedicine.com/interview-series/ ————————————————————————————— Visit our website: https://machinemedicine.com/ Connect with us on LinkedIn: https://www.linkedin.com/company/machine-medicine/
Two pain specialists discuss the latest research in spinal cord stimulation, and how it can be used to treat chronic pain. Kris Ferguson, MD welcomes Dr. Warren M. Grill, professor of Biomedical Engineering at Duke. Some patient testimonials from spinal cord stimulator implants are nothing short of miraculous. For those suffering from chronic pain, listening to this episode is a must! What exactly is neuromodulation? And do you ever wonder why rubbing a painful area makes it feel better? Warren M. Grill is Professor of Biomedical Engineering at Duke, where he studies electrical stimulation of the nervous system to restore function to individuals with neurological impairment or injury. Having won numerous awards and accolades, he is the 2018 winner of the Capers & Marion McDonald Award for Excellence in Teaching and Research, and in 2014 he won the Scholar/Teacher of the Year Award. Dr. Grill's Current projects include: • understanding the mechanisms of and developing advanced approaches to deep brain stimulation to treat movement disorders, • developing novel approaches to peripheral nerve electrical stimulation for restoration of bladder function, • understanding the mechanisms of and developing advanced approaches to spinal cord stimulation to treat chronic pain, • understanding and controlling the cellular effects of transcranial magnetic stimulation, and • design of novel electrodes and waveforms for selective stimulation of the nervous system.
On this episode of Metro Talks, we welcome Dr. Eric Fanaee of Long Island Brain and Spine to discuss treatment options available for people struggling with chronic axial low back pain. Dr. Eric K. Fanaee is a board-certified anesthesiologist with subspecialty certification in Pain Medicine. He received his medical degree from the University of Illinois College of Medicine, graduating with honors. After completing his residency in Anesthesiology at the University of Chicago, he finished fellowship training in Pain Medicine at the prestigious NYU Langone Medical Center.Dr. Fanaee is a member of many professional societies including the American Society of Anesthesiologists, American Society of Regional Anesthesiologists, and the American Academy of Pain Medicine. He has co-authored a textbook chapter for surgeons who specialize in pain management and has directed formal educational pain medicine courses for residents, fellows, and primary care doctors. He was the co-executive medical writer for the, now mandatory, pain medicine course required of all incoming NYU residents and attending physicians.Rising against the traditional ‘One size fits all’ paradigm, Dr. Fanaee believes in a multidisciplinary approach to pain management—incorporating medications, interventions, and physical modalities—to decrease a patient’s pain, maximize their function, and improve their overall quality of life. Dr. Fanaee wants each patient to enjoy life to the fullest and will stop at nothing to ensure that each patient achieves their goals. In addition to performing joint, spine, and soft tissue injections, Dr. Fanaee also utilizes advanced techniques such as Kyphoplasty, Spinal Cord Stimulation, Ultrasound Guided nerve blocks, and Radiofrequency Neurolysis where indicated.Dr. Fanaee takes his time to listen carefully to the needs of each individual patient, and he knows that many patients are interested in learning as much as possible about their conditions. He believes that the pain management consultation should be a place where patients can feel comfortable asking many questions and forming a therapeutic partnership with the physician.Check out Dr. Fanaee's office locations and schedule an appointment: http://longislandbrainandspine.com/eric-k-fanaee-m-d/Follow Dr. Fanaee on Instagram: @ericfanaeemdDr. Daniel Nagorski, PT, DPT, OCS, GTSDr. Nagorski graduated from Stony Brook University with his Doctorate degree in Physical Therapy. Previously, Dr. Nagorski received his Bachelor’s degree in Biology from SUNY Geneseo. He pursued a career in physical therapy due to a passion to helping people move better, and returning to their preferred activities. He has a strong background in orthopedic issues, and experience treating neurological disorders as well. He utilizes a wide assortment of therapeutic exercise, manual therapy, and neuromuscular reeducation in order to optimize your function, and allow you to achieve your goalsCheck out our new Huntington Station location and schedule an appointment: https://www.metrophysicaltherapy.com/huntington-stationIntracept Resources: https://www.metrophysicaltherapy.com/additionalresources/intraceptprocedure
Dr. Erika Petersen discusses her abstract, "Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy - Six Month Results from a Multicenter Randomized Controlled Trial". Show references: https://index.mirasmart.com/AAN2021/ Published article: https://jamanetwork.com/journals/jamaneurology/fullarticle/2777806
Interview with Erika Petersen, MD, author of Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial
Interview with Erika Petersen, MD, author of Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial
Dr. Falowski underwent his neurosurgical residency training at Thomas Jefferson University in Philadelphia with a focus on Spinal Cord Stimulation and Pain management, complex spinal procedures, and treatment for movement disorders such as deep brain stimulation. He completed a functional neurosurgical fellowship at Rush University in Chicago. His practice specializes in neuromodulation and spinal procedures. He is a past secretary and present senior advisor to the board for the North American Neuromodulation Society (NANS). He is on the board of directors of the International Neuromodulation Society (INS), and secretary of the executive pain committee for the Congress of Neurological Surgeons (CNS)/American Association of Neurological Surgeons (AANS). He also serves as an executive officer of the board for the American Society of Pain and Neuroscience. His major focus in society and industry revolves around education, integration of specialties, research, and practice management. Roles include implementing and directing the resident-fellows section and mentorship program through NANS. He has been the course director of the annual NANS spinal cord stimulation/neuromodulation workshop that is the largest training course available. He collaborates with numerous companies and industry partners on product development, education, research, and strategy. Dr. Falowski is involved in numerous clinical research studies and novel developments for spinal cord stimulation, pain management, deep brain stimulation, and spinal procedures. His passion and specialty interest deals with utilizing intra- operative neuromonitoring for the asleep placement of spinal cord stimulators, as well as developing new technologies and stimulation platforms Please check out the book "Integrating Pain Treatments into your Spine Practice" and visit the AANS Executive Pain Committee. Linked In-Steven Falowski sfalowski@gmail.com This podcast is powered by Pinecast.
Debilitating chronic pain causes people to be locked up inside their own bodies as prisoners. After years of suffering in this type of pain, patients see my brother Jimmy Lake, who works closely with the surgeons in the operating room, to install neuromodualtion implants into the patient's bodies. And once this cutting edge technology is installed and calibrated to meet his patients' pain needs, the patients can only express their relief in the from of tears of joy. From spinal cord stimulators to brain implants, Jimmy unpacks how this Boston Scientific technology is used to treat pain patients to get them off narcotics and back to a normal life. Jimmy is a Territory manager who oversees 5 employees working on the Sales Team for Boston Scientific in the Greater Seattle territory of Washington. His team has treated over 1000 patients from their pain. Additionally, his team has earned: -2014 highest revenue per rep in a territory out of the national wide sales teams -2015 and 2017 Presidents Club, this is the top 5% territories in the nation. -2018 highest revenue territory in the entire West Coast. Also I pick my brother's brain on ways that he lives by. We get Jimmy's life hacks and routines that lead him to live a successful life. We learn how he downloads his thoughts at the end of each day and how he uses reminders to help free up his mind to live a more stress free life. And finally, we talk about his leadership tactics and strategies he uses to lead his team to success. We learn the importance of giving praise to his employees to keep them engaged. Also, he mentions how giving his staff autonomy to get the job done as they see best fit offers big benefits in return. This episode is packed with a lot of content to better your life, advancements on pain technology and simple leadership ideas. Enjoy this wide ranging conversation with my brother and I. Let me know what you think about this episode on Twitter @David53032221 Time Start Table of Contents: 0:00:00 -Intro 0:03:57 -what this podcast is about 0:07:40 -life hacks, routines, running, public speaking 0:22:58 -Spinal Cord Stimulation w/Neuromodulation 0:30:03 -LED lighting therapy and high frequency combination therapy 0:33:48 -Neurolink, Brain Implants, Deep Brian Stimulation (DBS) 0:38:15 -North American Neuromodulation Society (NAMS) conference 0:42:25 -Migraine stimulation technology 0:48:15 -Employee Praise and autonomy 0:55:38 -conclusion References: https://www.bostonscientific.com/en-US/medical-specialties/pain-medicine/wavewriter-alpha-scs.html https://www.pain.com/en.html Podcast ref: For Jimmy's Tahoe stories, see The Tahoe Squad Podcast, episode 4: https://open.spotify.com/episode/5eWn2dIJC6MzvFDYctbH3g?si=xqxxcXMrTpCg92vmxHNpcA --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
We welcome Dr. Neel Mehta, Associate Professor of Anesthesiology and Director of Pain Management at Weill Cornell Medicine, as well as Co-Director of the Weill Cornell Center for Comprehensive Spine Care. Dr. Mehta specializes in interventional pain management with a focus on minimally invasive therapies and this episode focuses on how spinal cord stimulation is used as a method of pain management. We cover: (3:03) how spinal cord stimulators work and how to determine if you're a good candidate, (10:20) how this can help those with gastrointestinal motility and gastroparesis or the sensation that food is stuck in your esophagus, (12:18) how it could be helpful for those with diabetes, (14:45) the functional improvements spinal cord stimulation can provide, improving quality life, as well as the limitations of the treatment, and (18:00) why the treatment is an alternative to opioid use. Learn more about Dr. Mehta here: https://weillcornell.org/neelmehta
Back pain is one of the most common reasons people go to their health care provider or miss work, and it is a leading cause of disability worldwide. Most back pain gradually improves with home treatment and over-the-counter pain relievers. But for some people, back pain can be a debilitating problem that requires more advanced treatment. One option for persistent back pain is an implanted spinal cord stimulator that uses low levels of electricity to intercept or block pain signals. On the Mayo Clinic Q&A podcast, Dr. Tim Lamer, an anesthesiologist and pain medicine specialist at Mayo Clinic, explains how spinal cord stimulation devices are implanted and used to relieve persistent back pain.
Join Dr. Lubenow and Dr. Pope for the Abbott Virtual Scientific Forum Podcast, "In the Lupe: Industry Partnership" where they discuss the importance on partnering with Industry especially during the educational part of your fellowship. ReferencesProclaim™ DRG Neurostimulation System Clinician’s Manual. Plano, TX. 2018.Deer TR, Patterson DG, Baksh J, et al. Novel Intermittent Dosing Burst Paradigm in Spinal Cord Stimulation. Neuromodulation. Published online March 23, 2020. doi:10.1111/ner.13143. PMID: 32202044Diwan, Sudhir, and Timothy R. Deer. Advanced Procedures for Pain Management. Springer International Publishing:, 2018. https://www.springer.com/gp/book/9783319688398Rx OnlyBrief Summary: Prior to using these devices, please review the User’s Guide for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. The system is intended to be used with needles and electrodes that are compatible with the system.Indications for Use: The NT2000iX™ generator is intended for lesioning neural tissue. The NT2000iX™ generator is intended to be used for pain management. The NT2000iX™ generator is to be used only with separately cleared/approved lesion/temperature probes (NeuroTherm™ radiofrequency probes and SPINECATH™ and ACUTHERM™ catheters). The NT2000iX™ generator is indicated for use in the peripheral nervous system.Warnings/Precautions: Hazardous electrical output, Electric shock hazard, Explosion Hazard, Fire Hazard, Pooling Hazard, Ignition Hazard, Fuse Replacement, Risk of RF burns to patient, Interference with active implants, Interference with other equipment, Probes. User’s Guide must be reviewed for detailed disclosure. User’s Guide must be reviewed for detailed disclosure.DRGIndications for Use: US: Spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II.***Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study.**Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively. CRPS II (causalgia) is defined as a painful condition arising from damage to a nerve. Nerve damage may result from traumatic or surgical nerve injury. Changes secondary to neuropathic pain seen in CRPS I (RSD) may be present, but are not a diagnostic requirement for CRPS II (causalgia).International: Management of chronic intractable pain.Contraindications: US: Patients who are unable to operate the system, who are poor surgical risks. Patients who have failed to receive effective pain relief during trial stimulation.International: Patients who are unable to operate the system, are poor surgical risks, are pregnant, or under the age of 18.Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implantable devices, magnetic resonance imaging (MRI), computed tomography (CT), electrosurgery devices, ultrasonic scanning equipment, therapeutic radiation, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage.Adverse Effects: Unpleasant sensations, changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, tissue damage or nerve damage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain where needle was inserted or at the electrode site or at IPG site, seroma at implant site, headache, allergic or rejection response, battery failure and/or leakage. Clinician’s Manual must be reviewed for detailed disclosure.SCSIndications for Use: Spinal cord stimulation as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome and intractable low back and leg pain.Contraindications: Patients who are unable to operate the system or who have failed to receive effective pain relief during trial stimulation.Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implanted devices, magnetic resonance imaging (MRI), electrosurgery, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage. Patients who are poor surgical risks, with multiple illnesses, or with active general infections should not be implanted.Adverse Effects: Unpleasant sensations, changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain at the electrode or IPG site, seroma at IPG site, allergic or rejection response, battery failure. Clinician’s Manual must be reviewed for detailed disclosure.AbbottOne St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000Neuromodulation.Abbott™ Indicates a trademark of the Abbott group of companies.‡ Indicates a third party trademark, which is property of its respective owner.© 2020 Abbott. All Rights Reserved.MAT-2008840 v1.0 | Item approved for global use.
ReferencesProclaim™ DRG Neurostimulation System Clinician’s Manual. Plano, TX. 2018.Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017;158(4):669-681.Henderson, Jaimie M., et al. "NANS training requirements for spinal cord stimulation devices: selection, implantation, and follow‐up." Neuromodulation: Technology at the Neural Interface 12.3 (2009): 171-174.Deer, Timothy R., et al. "The Neurostimulation Appropriateness Consensus Committee (NACC) recommendations for infection prevention and management." Neuromodulation: Technology at the Neural Interface1 (2017): 31-50.Deer, Timothy R., et al. "The neurostimulation appropriateness consensus committee (NACC) safety guidelines for the reduction of severe neurological injury." Neuromodulation: Technology at the Neural Interface1 (2017): 15-30.Deer, Timothy R., et al. "The neuromodulation appropriateness consensus committee on best practices for dorsal root ganglion stimulation." Neuromodulation: Technology at the Neural Interface1 (2019): 1-35.Deer, Timothy R., et al. "Novel Intermittent Dosing Burst Paradigm in Spinal Cord Stimulation." Neuromodulation: Technology at the Neural Interface (2020).Tavel, Edward, et al. “Programming Optimization Strategies for Burst may Improve Outcomes.” NANS, Las Vegas, USA, 2017.*Smarter stimulation” described in the podcast at 15:53 is referring to neurostimulation with novel waveforms or parameters, and should not be described as “smart stimulation". Rx OnlyBrief Summary: Prior to using these devices, please review the User’s Guide for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. The system is intended to be used with leads and associated extensions that are compatible with the system.DRGIndications for Use: US: Spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II.***Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study.**Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively. CRPS II (causalgia) is defined as a painful condition arising from damage to a nerve. Nerve damage may result from traumatic or surgical nerve injury. Changes secondary to neuropathic pain seen in CRPS I (RSD) may be present, but are not a diagnostic requirement for CRPS II (causalgia).International: Management of chronic intractable pain.Contraindications: US: Patients who are unable to operate the system, who are poor surgical risks. Patients who have failed to receive effective pain relief during trial stimulation.International: Patients who are unable to operate the system, are poor surgical risks, are pregnant, or under the age of 18.Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implantable devices, magnetic resonance imaging (MRI), computed tomography (CT), electrosurgery devices, ultrasonic scanning equipment, therapeutic radiation, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage.Adverse Effects: Unpleasant sensations, changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, tissue damage or nerve damage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain where needle was inserted or at the electrode site or at IPG site, seroma at implant site, headache, allergic or rejection response, battery failure and/or leakage. Clinician’s Manual must be reviewed for detailed disclosure.SCSIndications for Use: Spinal cord stimulation as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome and intractable low back and leg pain.Contraindications: Patients who are unable to operate the system or who have failed to receive effective pain relief during trial stimulation.Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implanted devices, magnetic resonance imaging (MRI), electrosurgery, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage. Patients who are poor surgical risks, with multiple illnesses, or with active general infections should not be implanted.Adverse Effects: Unpleasant sensations, changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain at the electrode or IPG site, seroma at IPG site, allergic or rejection response, battery failure. Clinician’s Manual must be reviewed for detailed disclosure.AbbottOne St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000Neuromodulation.Abbott™ Indicates a trademark of the Abbott group of companies.‡ Indicates a third party trademark, which is property of its respective owner.© 2020 Abbott. All Rights Reserved.MAT-2006256 v1.0 | Item approved for global use.
ReferencesProclaim™ DRG Neurostimulation System Clinician’s Manual. Plano, TX. 2018.Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017;158(4):669-681.Deer T, et al. The Neuromodulation Appropriateness Consensus Committee on best practices for dorsal root ganglion stimulation. Neuromodulation. 2018;22(1):1-35.Kemler, M., Barendse, G., Kleef, M., Vet, H., Rijks, C., Furnée, C., Wildenberg, F. (2000). Spinal Cord Stimulation in Patients with Chronic Reflex Sympathetic Dystrophy The New England Journal of Medicine 343(9), 618-624. https://dx.doi.org/10.1056/nejm200008313430904Harden RN, Bruehl S, Perez RS, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain. 2010;150(2):268-274. doi:10.1016/j.pain.2010.04.030North, R., Kidd, D., Farrokhi, F., Piantadosi, S. (2005). Spinal Cord Stimulation versus Repeated Lumbosacral Spine Surgery for Chronic Pain: A Randomized, Controlled Trial Neurosurgery 56(1), 98-107. https://dx.doi.org/10.1227/01.neu.0000144839.65524.e0Deer T, et al. The Neuromodulation Appropriateness Consensus Committee on best practices for dorsal root ganglion stimulation. Neuromodulation. 2018;22(1):1-35.Jude Medical™ Proclaim™ Neurostimulation System Clinician’s Manual. Plano, TX 2018Deer T, Slavin KV, Amirdelfan K, et al. Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. Neuromodulation. 2017;20(6):543-552.Stauss T, et al. A multicenter real-world review of 10 kHz SCS outcomes for treatment of chronic trunk and/or limb pain. Annals of Clinical and Translational Neurology. 2019. doi:10.1002/acn3.720. * Up to 10 years of battery longevity at the lowest dose setting: 0.6mA, 500 Ohms, duty cycle 30s on/360s off. NOTE: In neurostimulation therapy, “dose” refers to the delivery of a quantity of energy to tissue. Safety comparisons and specific dose-response curves for each dosage have not been clinically established. Refer to the IFU for additional information.Hassle-free means recharge-free.** When compared to traditional tonic stimulation.***at 22:25 Speakers are referring to causalgia, not peripheral causalgia, this is defined in the ISI, see belowRx OnlyBrief Summary: Prior to using these devices, please review the User’s Guide for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. The system is intended to be used with leads and associated extensions that are compatible with the system.DRGIndications for Use: US: Spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II.***Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study.**Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively. CRPS II (causalgia) is defined as a painful condition arising from damage to a nerve. Nerve damage may result from traumatic or surgical nerve injury. Changes secondary to neuropathic pain seen in CRPS I (RSD) may be present, but are not a diagnostic requirement for CRPS II (causalgia).International: Management of chronic intractable pain.Contraindications: US: Patients who are unable to operate the system, who are poor surgical risks. Patients who have failed to receive effective pain relief during trial stimulation.International: Patients who are unable to operate the system, are poor surgical risks, are pregnant, or under the age of 18.Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implantable devices, magnetic resonance imaging (MRI), computed tomography (CT), electrosurgery devices, ultrasonic scanning equipment, therapeutic radiation, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage.Adverse Effects: Unpleasant sensations, changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, tissue damage or nerve damage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain where needle was inserted or at the electrode site or at IPG site, seroma at implant site, headache, allergic or rejection response, battery failure and/or leakage. Clinician’s Manual must be reviewed for detailed disclosure.SCSIndications for Use: Spinal cord stimulation as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome and intractable low back and leg pain.Contraindications: Patients who are unable to operate the system or who have failed to receive effective pain relief during trial stimulation.Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implanted devices, magnetic resonance imaging (MRI), electrosurgery, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage. Patients who are poor surgical risks, with multiple illnesses, or with active general infections should not be implanted.Adverse Effects: Unpleasant sensations, changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain at the electrode or IPG site, seroma at IPG site, allergic or rejection response, battery failure. Clinician’s Manual must be reviewed for detailed disclosure.AbbottOne St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000Neuromodulation.Abbott™ Indicates a trademark of the Abbott group of companies.‡ Indicates a third party trademark, which is property of its respective owner.© 2020 Abbott. All Rights Reserved.MAT-2006182 v1.0 | Item approved for global use.
A podcast for pain fellows covering topics that help you transition from fellowship to practice and give you the insight you need for real-world medicine. This episode introduces our hosts and shares insights on their pain medicine fellowship experiences. Please see our important safety information here https://www.neuromodulation.abbott/us/en/important-safety-info.htmlReferencesProclaim™ DRG Neurostimulation System Clinician’s Manual. Plano, TX. 2018.Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017;158(4):669-681.Deer T, et al. The Neuromodulation Appropriateness Consensus Committee on best practices for dorsal root ganglion stimulation. Neuromodulation. 2018;22(1):1-35.Kemler, M., Barendse, G., Kleef, M., Vet, H., Rijks, C., Furnée, C., Wildenberg, F. (2000). Spinal Cord Stimulation in Patients with Chronic Reflex Sympathetic Dystrophy The New England Journal of Medicine 343(9), 618-624. https://dx.doi.org/10.1056/nejm200008313430904Harden RN, Bruehl S, Perez RS, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain. 2010;150(2):268-274. doi:10.1016/j.pain.2010.04.030 North, R., Kidd, D., Farrokhi, F., Piantadosi, S. (2005). Spinal Cord Stimulation versus Repeated Lumbosacral Spine Surgery for Chronic Pain: A Randomized, Controlled Trial Neurosurgery 56(1), 98-107. https://dx.doi.org/10.1227/01.neu.0000144839.65524.e0 Rx OnlyBrief Summary: Prior to using these devices, please review the User’s Guide for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. The system is intended to be used with leads and associated extensions that are compatible with the system.Indications for Use: US: Spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II.***Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study.**Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively. CRPS II (causalgia) is defined as a painful condition arising from damage to a nerve. Nerve damage may result from traumatic or surgical nerve injury. Changes secondary to neuropathic pain seen in CRPS I (RSD) may be present, but are not a diagnostic requirement for CRPS II (causalgia).Contraindications: US: Patients who are unable to operate the system, who are poor surgical risks, or who have failed to receive effective pain relief during trial stimulation.Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implantable devices, magnetic resonance imaging (MRI), computed tomography (CT), electrosurgery devices, ultrasonic scanning equipment, therapeutic radiation, explosive or flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery and equipment, pediatric use, pregnancy, and case damage.Adverse Effects: Painful stimulation, loss of pain relief, surgical risks (e.g., paralysis). User’s Guide must be reviewed for detailed disclosure. Abbott One St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000 Neuromodulation.Abbott™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner. © 2020 Abbott. All Rights Reserved.MAT-2004708 v1.0 | Item approved for Global use.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.05.09.085647v1?rss=1 Authors: Yadav, A. P., Li, S., Krucoff, M. O., Lebedev, M. A., Abd-El-Barr, M. M., Nicolelis, M. A. L. Abstract: For patients who have lost sensory function due to a neurological injury such as spinal cord injury (SCI), stroke, or amputation, spinal cord stimulation (SCS) may provide a mechanism for restoring somatic sensations via an intuitive, non-visual pathway. We have previously shown that rats can learn to discriminate time-varying patterns of epidural SCS. Here we ran additional experiments in rats and conducted a new study in rhesus monkeys trained to discriminate patterns of epidural dorsal thoracic SCS. Based on these results, we constructed psychometric curves describing the relationship between different SCS parameters and the animal's ability to detect the presence of SCS and/or changes in its characteristics. We found that the stimulus detection threshold decreased with higher frequency, longer pulse-width, and increasing duration of SCS. Moreover, we found that monkeys were able to discriminate spatiotemporal patterns (i.e. variations in frequency and location) of SCS delivered through multiple electrodes. Additionally, the analysis of rat data showed that discrimination of SCS-induced sensations obeyed Weber's law of just noticeable differences. These findings suggest that by varying SCS intensity, temporal pattern and location different tactile and/or proprioceptive sensations can be evoked. As such, we posit that SCS can be used to provide intuitive sensory feedback in neuroprosthetic devices. Copy rights belong to original authors. Visit the link for more info
Drs. Bonner and Connor discuss spinal cord stimulation – how it works and who may benefit from it. For more information, please visit www.painconsultantsusa.com or reach out to us at info@painconsultantsusa.com
In this episode of Discussions in Spinal Cord Injury Science (DiSCIS), we interview Candy Tefertiller, PT, DPT, PhD, NCS about Transcutaneous Electrical Spinal Cord Stimulation. For more information, refer to: Taccola G, et al. And yet it moves: recovery of volitional control after spinal cord injury. Prog Neurobiol. 2018;160:64-81. The Spinal Cord Injury Special Interest Group is a part of the Academy of Neurologic Physical Therapy, www.neuropt.org.
Can neuromodulation be used to change the sensory transduction of the ischemic ventricle? To answer this question, Editor-in-Chief Dr. Irving H. Zucker (University of Nebraska Medical Center) interviewed lead author Jeffrey Ardell ( University of California Los Angeles) and content expert Marc Kaufman (Pennsylvania State University) about the new work by Salavatian et al. Ardell and co-authors found that preemptive spinal cord stimulation can reduce the afferent signal coming from the ischemic ventricle. Was this a result of a change in substrate utilization in the heart or was this “silent ischemia”? Does this spinal cord stimulation work by Ardell and collaborators have the potential to translate to reducing pain for patients with angina? Don’t miss the extra “off the record” commentary at the end to find out. Siamak Salavatian, Sarah M. Ardell, Mathew Hammer, David Gibbons, J. Andrew Armour, Jeffrey L. Ardell Thoracic spinal cord neuromodulation obtunds dorsal root ganglion afferent neuronal transduction of the ischemic ventricle Am J Physiol Heart Circ Physiol, published November 4, 2019. DOI: doi.org/10.1152/ajpheart.00257.2019
Back On The Beat - November 2, 2019 See omnystudio.com/listener for privacy information.
This presentation will highlight common procedures used for pain reduction, their evidence base, and a basic description of how each procedure is performed. We will primarily review epidural steroid injections, facet joint blocks and denervation, sacroiliac joint injections and denervation, myofascial pain, spinal cord stimulation, and intrathecal pumps. (Recorded at PAINWeek 2018)
Dr. Rosenblum discusses recent in advances in Neuromodulation. AnesthesiaExam Podcast App For iPhone and Android DISCLAIMER: Doctor Rosenblum IS HERE SOLELY TO EDUCATE, AND YOU ARE SOLELY RESPONSIBLE FOR ALL YOUR DECISIONS AND ACTIONS IN RESPONSE TO ANY INFORMATION CONTAINED HEREIN. This podcasts is not intended as a substitute for the medical advice of physician to a particular patient or specific ailment. You should regularly consult a physician in matters relating to yours or another’s health. You understand that this podcast is not intended as a substitute for consultation with a licensed medical professional. Copyright © 2018 QBazaar.com, LLC All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording or otherwise, without the prior written permission of the author. references Best Practices in Spinal Cord Stimulation Sitzman, B. Todd, MD, MPH∗; Provenzano, David A., MD† Spine: July 15, 2017 - Volume 42 - Issue - p S67-S71 doi: 10.1097/BRS.0000000000002220 FOCUS ISSUE ARTICLES Comparison of Tonic vs. Burst Spinal Cord Stimulation During Trial Period Laura Demartini MD et al First published: 17 October 2018 https://doi.org/10.1111/ner.12867 The Neurostimulation Appropriateness Consensus Committee (NACC) The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices Correction(s) for this article Timothy R. Deer MD Samer Narouze MD, PhD David A. Provenzano MD Jason E. Pope MD Steven M. Falowski MD Marc A. Russo MD Honorio Benzon MD First published: 02 January 2017 https://doi.org/10.1111/ner.12542
This presentation will highlight common procedures used for pain reduction, their evidence base, and a basic description of how each procedure is performed. We will primarily review epidural steroid injections, facet joint blocks and denervation, sacroiliac joint injections and denervation, myofascial pain, spinal cord stimulation, and intrathecal pumps. (Recorded at PAINWeek 2017)
Dr. Norman Shealy will discuss his newest research and discovery. Sorin Chakra Sweep PEMF near the head INCREASES gamma activity strikingly! HIGH GAMMA LEVELS are associated with high intelligence, creativity, happiness, compassion, self-control. Just 30 minutes of our PEMF increases brain, mind and body energy. Shealy will share his research findings and discuss the delivery method via scaler wave. C. Norman Shealy, M.D., Ph.D., D. Sc.is Founder and CEO of International Institute of Holistic Medicine, President of Shealy Wellness, LLC and Holos Energy Medicine Education. He is editor of Journal of Comprehensive Integrative Medicine. He was founding President of the American Holistic Medical Association in 1978. He was founding President of Holos University Graduate Seminary and is now Professor Emeritus of Energy Medicine. He has 12 patents in Energy Medicine, has published 35 books and over 300 articles. Dr. Shealy’s innovations include Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS), the RejuvaMatrix® for rejuvenating telomeres, and Transcutaneous Acupuncture, which has now also been shown to rejuvenate telomeres for healthy longevity. His clinical work includes comprehensive holistic management of pain, depression, anxiety, and cardiovascular problems, emphasizing TENS, PEMF, vibratory and binaural music, nutrition, Biogenics retraining of the nervous system, and healthy longevity. His latest discoveries are the use of Sapphire enhanced AdrenoScalar® for reduction of stress, adrenomedullin, free radicals and inflammation AND the Chakra-Sweep PEMF for gamma brain activity. His latest book is CONVERSATIONS with G: A physician’s encounter with heaven. To learn more about Provocative Enlightenment Radio, go to http://www.provocativeenlightenment.com
Comparison of 10 kHz High Frequency and Traditional Low Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-month Results From a Multicenter Randomized Controlled Pivotal Trial Article link: Comparison of 10 kHz High Frequency and Traditional Low Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-month Results From a Multicenter Randomized Controlled Pivotal Trial Participants: •Master of Ceremonies: Dr. Martina Stippler, CNS Resident Committee Chair •Author/Presenter: Dr. Leonardo Kapural •CNS Faculty: Dr. Jason Schwalb, CNS Faculty •Discussant: Dr. Pratik Rohatgi, Leadership Fellow
Neurostimulation is advancing in exciting ways. One such innovation is called high frequency spinal cord stimulation which does not cause a tingling sensation. In fact, it just replaces the pain, with pain relief. Studies suggest that it may better control chronic low back pain too. Robin describes how this new spinal cord stimulator changed her … The post High Frequency Spinal Cord Stimulation, Part I appeared first on Dr. Paul Christo MD.
Neurostimulation is advancing in exciting ways. One such innovation is called high frequency spinal cord stimulation which does not cause a tingling sensation. In fact, it just replaces the pain, with pain relief. Studies suggest that it may better control chronic low back pain too. Robin describes how this new spinal cord stimulator changed her … The post High Frequency Spinal Cord Stimulation, Part II appeared first on Dr. Paul Christo MD.
Raj, Eric, Gary, and Larry discuss the differences between spinal cord stimulator, high-frequency SCS, and dorsal root ganglion (DRG) stimulation.Hosts:- Raj Gupta MD, Vanderbilt University Medical Center (@dr_rajgupta)- Eric Schwenk MD, Sidney Kimmel Medical College at Thomas Jefferson University (@ESchwenkMD)Guests:- Gary Schwartz MD, Maimonides Medical Center and AABP (@garyschwartzmd)- Larry Epstein MD, Mount Sinai Hospital (@gdtrfb58)Articles:A Multicenter, Prospective Trial to Assess the Safety and Performance of the Spinal Modulation Dorsal Root Ganglion Neurostimulator System in the Treatment of Chronic Pain(http://onlinelibrary.wiley.com/doi/10.1111/ner.12072/full#ner12072)Dorsal Root Ganglion (DRG) Stimulation in the Treatment of Phantom Limb Pain (PLP)(http://onlinelibrary.wiley.com/doi/10.1111/ner.12338/full#ner12338)One-Year Outcomes of Spinal Cord Stimulation of the Dorsal Root Ganglion in the Treatment of Chronic Neuropathic Pain(http://onlinelibrary.wiley.com/doi/10.1111/ner.12228/full#ner12228)Sustained Effectiveness of 10 kHz High-Frequency Spinal Cord Stimulation for Patients with Chronic, Low Back Pain: 24-month Results of a Prospective Multicenter Study(http://painmedicine.oxfordjournals.org/content/15/3/347.long)10-kHz High-Frequency SCS Therapy: A Clinical Summary(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660894/) _____Thanks to The Preps from Philadelphia, PA for the music: “Funkcore" and "Unknown Night". The band features Steve Breslin on vocals/guitars, Bryan Schwenk on guitars/vocals, Jeff Frederick on bass, and Eric Schwenk on drums.
Question: A patient asks the nurse about spinal cord stimulation as a method of pain control. Which of the following describes an element of this type of pain management? Select all that apply. Answer: A. The patient has wires inserted into the back to receive the stimulation B. Spinal cord stimulation has been successfully used to treat […] The post QOD 65: Spinal Cord Stimulation (Pharmacology/Basic Care and Comfort) appeared first on NURSING.com.
NRSNG NCLEX® Question of the Day (Nursing Podcast for NCLEX® Prep and Nursing School)
Question: A patient asks the nurse about spinal cord stimulation as a method of pain control. Which of the following describes an element of this type of pain management? Select all that apply. Answer: A. The patient has wires inserted into… The post QOD 65: Spinal Cord Stimulation (Pharmacology/Basic Care and Comfort) appeared first on NURSING.com.
Nerve stimulation with small doses of electricity has been used for pain relief since Egyptian and Roman times. In this show, we’ll learn about exciting advances in neurostimulation for controlling pain. Andy Magruder shares his compelling story of how a pain pacemaker transformed his life following three spinal surgeries. And then, Dr. Giancarlo Barolat, neurosurgeon … The post Innovations in Spinal Cord Stimulation appeared first on Dr. Paul Christo MD.
Back pain is one of the most common reasons people go to their health care provider or miss work, and it is a leading cause of disability worldwide. Most back pain gradually improves with home treatment and over-the-counter pain relievers. But for some people, back pain can be a debilitating problem that requires more advanced treatment. One option for persistent back pain is an implanted spinal cord stimulator that uses low levels of electricity to intercept or block pain signals. On the Mayo Clinic Q&A podcast, Dr. Tim Lamer, an anesthesiologist and pain medicine specialist at Mayo Clinic, explains how spinal cord stimulation devices are implanted and used to relieve persistent back pain. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
© 2020-2025 Ivy Podcast Discovery LLC
